NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00884325,Management of Pruritus With Xyzal in Atopic Dermatitis,https://clinicaltrials.gov/study/NCT00884325,,COMPLETED,"It is historically well known that the management of pruritus in atopic dermatitis is very difficult. Most of the patients are not controlled with traditional antihistamines such as Clarinex, Claritin, and Allegra. It will be a welcome addition to our treatment armamentarium if a drug such as Xyzal can control pruritus associated with atopic dermatitis.",YES,Atopic Dermatitis|Pruritus,DRUG: Levocetirizine dihydrochloride (Xyzal)|DRUG: placebo,"Pruritus VAS Scores at Baseline, Week 2 and Week 4, Consented subjects who met inclusion/exclusion criteria were assigned either 5mg levocetirizine dihydrochloride (Xyzal) or placebo to be taken daily each evening for 28 days. Subjects were asked to complete a Visual Analog Scale to measure itch at Baseline, Week 2 and Week 4. The scale is an eleven point scale ranging from 0-10 with 0 indicating no itch to 10 indicating itch that frequently interferes with daily activities., Baseline - Week 2-Week 4","Dermatology Life Quality Index (DLQI) Questionnaire Scores at Baseline, Week 2 and Week 4, Consented subjects who met inclusion/exclusion criteria were asked to complete a DLQI (Dermatology Life Quality Index)at Baseline, Week 2 and Week 4. The DLQI is a 10 item questionnaire broken down into 6 domains; symptoms and feelings, daily activities, leisure, work and school, personal relationships and treatment with a total score ranging from 0-30 (no effect on subject's life for 0, extremely large effect on subject's life for 30), Baseline - Week 2 - Week 4",,"Derm Research, PLLC",UCB Pharma,ALL,"ADULT, OLDER_ADULT",PHASE4,40,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",XYZ0801,2009-02,2010-01,2010-01,2009-04-20,2013-04-23,2013-08-16,"DermResearch, PLLC, Louisville, Kentucky, 40217, United States",
